Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Is Axonal Degeneration a Key Early Event in Parkinson's Disease?

Kurowska Z, Kordower JH, Stoessl AJ, Burke RE, Brundin P, Yue Z, Brady ST, Milbrandt J, Trapp BD, Sherer TB, Medicetty S.

J Parkinsons Dis. 2016 Oct 19;6(4):703-707. Review.

PMID:
27497486
2.

Parkinson's disease is ready for precision medicine.

Sherer TB, Frasier MA, Langston JW, Fiske BK.

Per Med. 2016 Sep;13(5):405-407. doi: 10.2217/pme-2016-0052. Epub 2016 Aug 9. No abstract available.

3.

Nilotinib - Differentiating the Hope from the Hype.

Wyse RK, Brundin P, Sherer TB.

J Parkinsons Dis. 2016 Jul 12;6(3):519-22. doi: 10.3233/JPD-160904.

4.

Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease.

Dave KD, De Silva S, Sheth NP, Ramboz S, Beck MJ, Quang C, Switzer RC 3rd, Ahmad SO, Sunkin SM, Walker D, Cui X, Fisher DA, McCoy AM, Gamber K, Ding X, Goldberg MS, Benkovic SA, Haupt M, Baptista MA, Fiske BK, Sherer TB, Frasier MA.

Neurobiol Dis. 2014 Oct;70:190-203. doi: 10.1016/j.nbd.2014.06.009. Epub 2014 Jun 24.

5.

Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.

Ko WK, Pioli E, Li Q, McGuire S, Dufour A, Sherer TB, Bezard E, Facheris MF.

Mov Disord. 2014 May;29(6):772-9. doi: 10.1002/mds.25859. Epub 2014 Mar 7.

PMID:
24610195
6.

Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs.

Baptista MA, Dave KD, Frasier MA, Sherer TB, Greeley M, Beck MJ, Varsho JS, Parker GA, Moore C, Churchill MJ, Meshul CK, Fiske BK.

PLoS One. 2013 Nov 14;8(11):e80705. doi: 10.1371/journal.pone.0080705. eCollection 2013.

7.

A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research.

Baptista MA, Dave KD, Sheth NP, De Silva SN, Carlson KM, Aziz YN, Fiske BK, Sherer TB, Frasier MA.

Dis Model Mech. 2013 Nov;6(6):1316-24. doi: 10.1242/dmm.011940. Epub 2013 Sep 12.

8.

Money without collaboration won't bring cures.

Sherer TB.

Nat Med. 2013 Feb;19(2):127. doi: 10.1038/nm0213-127. No abstract available.

PMID:
23389601
9.

Overcoming obstacles in Parkinson's disease.

Sherer TB, Chowdhury S, Peabody K, Brooks DW.

Mov Disord. 2012 Nov;27(13):1606-11. doi: 10.1002/mds.25260. Epub 2012 Oct 31. Review.

PMID:
23115047
10.

Biomarkers for Parkinson's disease.

Sherer TB.

Sci Transl Med. 2011 Apr 20;3(79):79ps14. doi: 10.1126/scitranslmed.3002488.

PMID:
21508309
11.

Special focus section: gene therapy for Parkinson's disease.

Fiske BK, Frasier MA, Sherer TB.

Exp Neurol. 2008 Jan;209(1):28-9. Epub 2007 Sep 18. No abstract available.

PMID:
17980867
12.

Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease.

Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T, Matsuno-Yagi A, Miller GW, Greenamyre JT.

J Neurochem. 2007 Mar;100(6):1469-79. Epub 2007 Jan 4.

13.

Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Richardson JR, Caudle WM, Guillot TS, Watson JL, Nakamaru-Ogiso E, Seo BB, Sherer TB, Greenamyre JT, Yagi T, Matsuno-Yagi A, Miller GW.

Toxicol Sci. 2007 Jan;95(1):196-204. Epub 2006 Oct 12.

PMID:
17038483
14.

Crossroads in GDNF therapy for Parkinson's disease.

Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW.

Mov Disord. 2006 Feb;21(2):136-41.

PMID:
16470786
15.

Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.

Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, Lund S, Na HM, Taylor G, Bence NF, Kopito R, Seo BB, Yagi T, Yagi A, Klinefelter G, Cookson MR, Greenamyre JT.

Neurobiol Dis. 2006 May;22(2):404-20. Epub 2006 Jan 24.

PMID:
16439141
16.

Paraquat neurotoxicity is distinct from that of MPTP and rotenone.

Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW.

Toxicol Sci. 2005 Nov;88(1):193-201. Epub 2005 Sep 1.

PMID:
16141438
17.

Oxidative damage in Parkinson's disease.

Sherer TB, Greenamyre JT.

Antioxid Redox Signal. 2005 May-Jun;7(5-6):627-9. No abstract available.

PMID:
15890006
18.

Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.

Testa CM, Sherer TB, Greenamyre JT.

Brain Res Mol Brain Res. 2005 Mar 24;134(1):109-18. Epub 2005 Jan 6.

PMID:
15790535
19.

Ubiquitin-proteasome system and Parkinson's diseases.

Betarbet R, Sherer TB, Greenamyre JT.

Exp Neurol. 2005 Feb;191 Suppl 1:S17-27. Review.

PMID:
15629758
20.

Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.

Caboni P, Sherer TB, Zhang N, Taylor G, Na HM, Greenamyre JT, Casida JE.

Chem Res Toxicol. 2004 Nov;17(11):1540-8.

PMID:
15540952
21.
22.

Mechanism of toxicity in rotenone models of Parkinson's disease.

Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT.

J Neurosci. 2003 Nov 26;23(34):10756-64.

23.

The rotenone model of Parkinson's disease: genes, environment and mitochondria.

Greenamyre JT, Betarbet R, Sherer TB.

Parkinsonism Relat Disord. 2003 Aug;9 Suppl 2:S59-64. Review.

PMID:
12915069
24.

Pesticides and Parkinson's disease.

Sherer TB, Betarbet R, Greenamyre JT.

ScientificWorldJournal. 2001 May 1;1:207-8. Review.

25.

Selective microglial activation in the rat rotenone model of Parkinson's disease.

Sherer TB, Betarbet R, Kim JH, Greenamyre JT.

Neurosci Lett. 2003 May 1;341(2):87-90.

PMID:
12686372
26.

Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.

Sherer TB, Kim JH, Betarbet R, Greenamyre JT.

Exp Neurol. 2003 Jan;179(1):9-16.

PMID:
12504863
27.

Mechanistic approaches to Parkinson's disease pathogenesis.

Betarbet R, Sherer TB, Di Monte DA, Greenamyre JT.

Brain Pathol. 2002 Oct;12(4):499-510. Review.

PMID:
12408237
28.

An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT.

J Neurosci. 2002 Aug 15;22(16):7006-15.

29.

Environment, mitochondria, and Parkinson's disease.

Sherer TB, Betarbet R, Greenamyre JT.

Neuroscientist. 2002 Jun;8(3):192-7. Review.

PMID:
12061498
30.

Animal models of Parkinson's disease.

Betarbet R, Sherer TB, Greenamyre JT.

Bioessays. 2002 Apr;24(4):308-18. Review.

PMID:
11948617
31.

Complex I and Parkinson's disease.

Greenamyre JT, Sherer TB, Betarbet R, Panov AV.

IUBMB Life. 2001 Sep-Nov;52(3-5):135-41. Review.

32.

Pathogenesis of Parkinson's disease.

Sherer TB, Betarbet R, Greenamyre JT.

Curr Opin Investig Drugs. 2001 May;2(5):657-62. Review.

PMID:
11569943
33.

Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells.

Sherer TB, Trimmer PA, Borland K, Parks JK, Bennett JP Jr, Tuttle JB.

Brain Res. 2001 Feb 9;891(1-2):94-105.

PMID:
11164812
34.

Chronic systemic pesticide exposure reproduces features of Parkinson's disease.

Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT.

Nat Neurosci. 2000 Dec;3(12):1301-6.

PMID:
11100151
35.

Mitochondrial DNA-depleted neuroblastoma (Rho degrees) cells exhibit altered calcium signaling.

Sherer TB, Trimmer PA, Parks JK, Tuttle JB.

Biochim Biophys Acta. 2000 Apr 17;1496(2-3):341-55.

36.

Calcium homeostasis and nerve growth factor secretion from vascular and bladder smooth muscle cells.

Sherer TB, Clemow DB, Tuttle JB.

Cell Tissue Res. 2000 Feb;299(2):201-11.

PMID:
10741461
37.

Mitochondrial impact on nerve growth factor production in vascular smooth muscle-derived cells.

Sherer TB, Neff PS, Parks JK, Tuttle JB.

Biochim Biophys Acta. 1999 Dec 27;1473(2-3):305-20.

PMID:
10594368
38.

The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males.

Steers WD, Clemow DB, Persson K, Sherer TB, Andersson KE, Tuttle JB.

Exp Physiol. 1999 Jan;84(1):137-47. Review.

PMID:
10081714
39.
40.

Mechanisms of increased NGF production in vascular smooth muscle of the spontaneously hypertensive rat.

Sherer TB, Neff PS, Hankins GR, Tuttle JB.

Exp Cell Res. 1998 May 25;241(1):186-93.

PMID:
9633527
41.

Thrombin regulates nerve growth factor secretion from vascular, but not bladder smooth muscle cells.

Sherer TB, Spitsbergen JM, Steers WD, Tuttle JB.

Cell Tissue Res. 1997 Jul;289(1):155-61.

PMID:
9182610

Supplemental Content

Loading ...
Support Center